Eyenovia Inc ( EYEN ) shares are surging Monday in response to the company’s announcement of the launch of a new FDA-approved ophthalmic drug in collaboration with Formosa Pharmaceuticals.

Key Developments:

Eyenovia ( EYEN ) and Formosa Pharma have launched APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%), the first FDA-approved ophthalmic drug using clobetasol propionate, a super-potent corticosteroid. The drug is designed for treating postoperative inflammation and pain following eye surgery.

The ophthalmic steroid market in the U.S. is valued at approximately $1.3 billion, and nearly seven million ophthalmic surgeries are performed annually. Eyenovia’s new product stands out due to its twice-daily dosing regimen, compared to up to four doses per day for other treatments, making it a cost-effective and more convenient option.

Formosa Pharmaceuticals made its first shipment of the drug to the U.S. for commercialization, with Eyenovia ( EYEN ) expected to begin full-scale commercialization later in September 2024. This drug was developed using Formosa's proprietary APNT nanotechnology platform.

The company has initiated pre-launch activities for the product, signaling momentum toward capturing market share in the growing ophthalmic sector.

What Else: This news is also trending across financial platforms and social media as investors speculate the product's market entry could significantly boost Eyenovia's ( EYEN ) revenues and market presence in the ophthalmic space.

EYEN Price Action: Eyenovia's ( EYEN ) stock has spiked by 14.94%, reaching 0.57 cents at market close Monday, according to Benzinga pro.

See Also:

Do You Know What It Takes To Be ‘Wealthy’ When Retired? Here’s What The Top 5% Of Retirees Have In Their Nest Eggs

Image Via Shutterstock.